ClinicalTrials.gg
CompletedNCT03088267Updated Jul 22, 2019Results posted

Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study

A Phase 3 interventional study of amphetamine extended-release oral suspension, 2.5 mg/mL and Placebo extended-release oral suspension in Attention Deficit Hyperactivity Disorder, sponsored by Tris Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2019-07-22.

Sponsored by Tris Pharma, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
616th of 706
18 · median 70
Started
2017
with 33 others
Phase 3
121 of 807
4 open now
Registered
490th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 616th largest by enrollment of the 706 interventional ones that give a count, is one of 34 that started in 2017, is one of 121 in phase 3, and was the 490th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12 years.

Read the detailed description

This is a randomized, double-blind, two treatment, two sequence, placebo-controlled crossover study to assess the efficacy and safety of dose Dyanavel XR in reducing signs and symptoms of ADHD compared with placebo in pediatric subjects ages 6 to 12 years with ADHD.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged 6 to 12 years at the time of screening, inclusive
  2. Diagnosed with ADHD by a psychiatrist within 6 months of study enrolment or newly diagnosed with ADHD using the criteria for ADHD
  3. An ADHD-RS-5 score at Screening ≥90th percentile for sex and age in at least one of the following categories:

    1. Hyperactive-impulsive subscale,
    2. Inattentive subscale, or
    3. Total score. Subjects who do not meet this criteria at screening can have ADHD-RS-5 repeated at baseline, after washout of stimulant medication for a minimum of 24 hours prior to baseline.
  4. In the clinical judgment of the Investigator, the subject must be in need of pharmacological treatment for ADHD.
  5. Females of must be non-lactating and must have a negative serum pregnancy test at screening
  6. Provide written (parent/guardian) and assent (child aged 10 - 12 years only) prior to participation in the study

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with any active disorder (other than ADHD) with the exception of specific phobias, learning disorders, motor skills disorders, communication disorders, oppositional defiant disorder, elimination disorders, and sleep disorders
  2. Known history of chronic medical illnesses including severe hypertension, untreated thyroid disease, peripheral vasculopathy, known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, cardiomyopathy, known family history of sudden death
  3. Known history or presence of significant renal or hepatic disease, as indicated by clinical laboratory assessment (liver function test results ≥ two times the , blood urea nitrogen, or creatinine).
  4. abnormal or cardiac findings on physical examination (including the presence of a pathologic murmur)
  5. Use of the following medications within 30 days of Baseline Visit:

    • MAOI - monoamine oxidase inhibitors (e.g., Selegiline, isocarboxazid, phenelzine, tranylcypromine)
    • Tricyclic Antidepressants (e.g. Desipramine, protriptyline)
  6. Use of the following medications within 3 days of Baseline Visit

    • Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid HCl, ascorbic acid)
    • Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts)
  7. Use of atomoxetine within 14 days of Baseline Visit
  8. Planned use of prohibited drugs or agents from the Screening visit through the end of the study
  9. Abnormal clinically significantly laboratory test value at screening that, in the opinion of the Investigator, would preclude study participation
  10. Known history of allergy/ to amphetamine or any of the components of Dyanavel XR, or topical anaesthetics
  11. Known history of lack of response to amphetamine
  12. Parent or guardian's inability or unwillingness to follow directions of the Investigator or study research staff.
  13. Any uncontrolled medical condition that in the opinion of the Investigator would preclude study participation
  14. History of significant illness requiring hospitalization, or surgery requiring anaesthetics within 30 days of Baseline Visit
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Active comparator
    Active Treatment

    Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM

    Drug: amphetamine extended-release oral suspension, 2.5 mg/mL · Drug: Placebo extended-release oral suspension

  • Placebo comparator
    Placebo Treatment

    Double blind placebo, 6, 7 or 8 mL po QAM

    Drug: amphetamine extended-release oral suspension, 2.5 mg/mL · Drug: Placebo extended-release oral suspension

Interventions

  • Drugamphetamine extended-release oral suspension, 2.5 mg/mL

    Drug page: Amphetamine

    5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO

    Also known as: Dyanavel XR

  • DrugPlacebo extended-release oral suspension

    6, 7 or 8 mL PO

06

What researchers measure

Primary outcomes

  1. Change in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores, Baseline to 30 Minutes Post Dose

    Change in SKAMP-C (Swanson, Kotkin, Agler, M-Flynn, and Pelham combined) score from pre-dose, by treatment. The SKAMP-C is a rating scale that assesses functional impairment related to ADHD in the classroom, including the performance of academic tasks, following class rules, and interacting with peers and adults in the classroom. The SKAMP-C is a 13-item, 7-score rating system (0=normal to 7=maximal impairment). The higher the score, the worse the impairment. A decrease from baseline in the combined (all 13 items) score indicates improvement. The SKAMP-C is used to assess the time course of treatment effects in laboratory classroom studies.

    Time frame: Change in SKAMP-C score from baseline to 30 minutes postdose.

Secondary outcomes

  1. Change in Permanent Product Measure of Performance (PERMP-C) Score (Problems Answered Correctly)

    Change from pre-dose in PERMP-C scores (Permanent Product Measure of Performance; defined as the number of problems attempted and number of problems solved correctly) at 30 minutes post-dose and at 3 hours post-dose. The PERMP-C is designed to assess compliance and academic productivity in school children. It is a 10-minute timed test in which the number of problems attempted and correct are assessed prior to and after an intervention. Scoring is based on problems attempted and correct. An increase in numerical score is indicative of improvement.

    Time frame: 30 minutes postdose and 3 hours postdose

07

Results

Posted Jul 9, 2019

Participant flow

Date first subject enrolled: February 11, 2017 Date last subject completed: February 25, 2017

Participant flow — Overall Study
MilestoneSequence: AMPH EROS/PlaceboSequence: Placebo/AMPH EROS
Started99
Completed99
Not completed00

Outcome measures

PrimaryChange in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores, Baseline to 30 Minutes Post Dose

Change in SKAMP-C (Swanson, Kotkin, Agler, M-Flynn, and Pelham combined) score from pre-dose, by treatment. The SKAMP-C is a rating scale that assesses functional impairment related to ADHD in the classroom, including the performance of academic tasks, following class rules, and interacting with peers and adults in the classroom. The SKAMP-C is a 13-item, 7-score rating system (0=normal to 7=maximal impairment). The higher the score, the worse the impairment. A decrease from baseline in the combined (all 13 items) score indicates improvement. The SKAMP-C is used to assess the time course of treatment effects in laboratory classroom studies.

Time frame:
Change in SKAMP-C score from baseline to 30 minutes postdose.
Reported as:
Least squares mean · number of questions answered correctly
Change in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores, Baseline to 30 Minutes Post Dose
number of questions answered correctlyActive TreatmentPlacebo Treatment
Change in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores, Baseline to 30 Minutes Post Dose-6.1 ± 2.292.5 ± 2.29
Statistical analysis
  • Active Treatment vs Placebo Treatment · ANCOVA · p = 0.0118 · Mean difference (final values): -8.6 · 95% CI -14.94 to -2.17
SecondaryChange in Permanent Product Measure of Performance (PERMP-C) Score (Problems Answered Correctly)

Change from pre-dose in PERMP-C scores (Permanent Product Measure of Performance; defined as the number of problems attempted and number of problems solved correctly) at 30 minutes post-dose and at 3 hours post-dose. The PERMP-C is designed to assess compliance and academic productivity in school children. It is a 10-minute timed test in which the number of problems attempted and correct are assessed prior to and after an intervention. Scoring is based on problems attempted and correct. An increase in numerical score is indicative of improvement.

Time frame:
30 minutes postdose and 3 hours postdose
Reported as:
Least squares mean · Change from baseline in PERMP score
Change in Permanent Product Measure of Performance (PERMP-C) Score (Problems Answered Correctly)
Change from baseline in PERMP scoreActive TreatmentPlacebo Treatment
Change from predose in PERMP-C at 30 minutes14.4 ± 7.25-4.7 ± 7.25
Change from predose in PERMP-C at 3 hours52.4 ± 9.43-7.9 ± 9.43
Statistical analysis
  • Active Treatment vs Placebo Treatment · ANCOVA · p = 0.1128 · Mean difference (final values): 18.8 · 95% CI -4.94 to 42.50
  • Active Treatment vs Placebo Treatment · ANCOVA · p = 0.0003 · Mean difference (final values): 60.3 · 95% CI 32.91 to 87.75

Adverse events

Collected over The duration of the study (5 weeks from screening to final follow-up assessment). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AMPH EROS: Open Label Phase0/18 (0%)0/18 (0%)6/18 (33.3%)
Crossover Phase: AMPH EROS0/18 (0%)0/18 (0%)0/18 (0%)
Crossover Phase: Placebo0/18 (0%)0/18 (0%)0/18 (0%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAMPH EROS: Open Label PhaseCrossover Phase: AMPH EROSCrossover Phase: Placebo
Upper respiratory tract infectionInfections and infestations4/18——
FatigueGeneral disorders3/18——
Abdominal pain, upperGastrointestinal disorders2/18——
HeadacheNervous system disorders2/18——
Decreased appetiteMetabolism and nutrition disorders2/18——
Affect labilityPsychiatric disorders2/18——
BronchitisInfections and infestations1/18——
Respiratory tract viral infectionInfections and infestations1/18——
DiarrheaGastrointestinal disorders1/18——
Motion sicknessNervous system disorders1/18——

Baseline characteristics

Age, Customized
Age, Customized(years)Overall Study
Median10 (6 to 11)
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female4
Male14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino5
Not Hispanic or Latino13
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White16
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall Study
United States18
08

Study locations

1 site
  • Center for Psychiatry and Behavioral Medicine
    Las Vegas, Nevada 89128, United States
09

References and documents

Publications

  • Childress AC, Kando JC, King TR, Pardo A, Herman BK. Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2019 Feb;29(1):2-8. doi: 10.1089/cap.2018.0078. Epub 2018 Dec 21. PubMed 30575407 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Feb 2017, 0 months.

Results were first posted in Jul 2019, 2 years 4 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 0 months is below that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2017
First posted
Mar 23, 2017
StartActual
Feb 11, 2017
Primary completionActual
Feb 25, 2017
CompletionActual
Oct 30, 2017
Results first posted
Jul 9, 2019
Last update
Jul 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03088267
Lead sponsor
Tris Pharma, Inc.
Responsible party
Sponsor
First posted
Mar 23, 2017
Start date
Feb 11, 2017
Primary completion
Feb 25, 2017
Completion
Oct 30, 2017
Results posted
Jul 9, 2019
Last update
Jul 22, 2019

Study contacts

Sally Berry, MD, PhD
study chair · Tris Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amphetamine

Start the discussion